Physician profile
Wayne D Siegel
NPI 1063409191
$493.03
in general payments reported to CMS, 2019-2025
9 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.93 · 2020: $14.42 · 2021: $55.36 · 2022: $25.63 · 2023: $43.16 · 2024: $162 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $256.61 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $67.45 | 2020-2023 | |
| Abbvie INC. | $55.91 | 2023-2025 | Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.05 | 2023-2024 | Trulance |
| Conmed Corporation | $28.30 | 2021 | |
| Novo Nordisk INC | $14.96 | 2025 | Wegovy |
| Capsovision, INC. | $13.96 | 2025 | Capsocam Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $13.93 | 2019 | |
| Glaxosmithkline, LLC. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.